Exploring novel prognostic biomarkers and biologic processes involved in NASH, cirrhosis and HCC based on survival analysis using systems biology approach

Sedigheh Behrouzifar

2023-06-28

Abstract:There is an unmet need to develop medications or drug combinations which can stop advancement of NASH to liver cirrhosis and HCC. Therefore, identifying key biomarkers based on overall survival and the exploring biological processes involved in the pathogenesis and progression of NASH toward cirrhosis and HCC to improve therapeutic interventions is necessary. The microarray dataset from the GPL13667 platform was downloaded from the Gene Expression Omnibus (GEO). The inclusion criteria for the DEGs included an adjusted p-value <0.05 and a log(2) fold change >1. In the first step, protein-protein interaction (PPI) network of differentially expressed genes (DEGs) in every three groups (NASH, Cirrhosis and HCC) was constructed using STRING online database. In the second step, the DEGs of each group were imported to Cytoscape software separately, and the genes with Degree >3 were selected. In the third step, the genes with Degree >3 were imported to Gephi software (0.9.2 version) and the genes with betweenness centrality >0 were selected. Venn diagram of these genes was depicted for the NASH, cirrhotic and HCC groups. According to venn diagram, 96 (NASH), 30 (cirrhotic) and 213 (HCC) genes were specifically upregulated (based on inclusion criteria). Among specific genes, 22 (NASH), 5 (cirrhotic) and 82 (HCC) genes were with poor overall survival. The overlap among the 3 groups (NASH, Cirrhosis and HCC) contained 4 upregulated genes HLA-F, HLA-DPA1, TPM1 and YWHAZ. From 4 upregulated genes, only YWHAZ gene was with poor overall survival. The present study detected new candidate genes and key biological processes in NASH, cirrhosis and HCC based on overall survival and using in silico analysis. Therefore, performing in vitro and in vivo researches to verify the results is necessary.

Molecular Networks

What problem does this paper attempt to address?

The main objective of this paper is to explore novel prognostic biomarkers and related biological processes in non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC) using systems biology methods based on survival analysis. Specifically, the study aims to:

1. **Identify key biomarkers**: Determine specific upregulated genes associated with the progression of NASH, cirrhosis, and HCC by analyzing gene expression data, particularly those related to poor overall survival rates.

2. **Explore biological processes**: Understand the biological processes involving these specific upregulated genes, including but not limited to cytokine-mediated signaling pathways, negative regulation of programmed cell death, regulation of MAPK cascade, etc.

3. **Screen potential therapeutic targets**: Screen key proteins that may serve as therapeutic targets through network analysis and functional enrichment analysis of differentially expressed genes (DEGs), and gain deeper insights into the roles of these targets in disease onset and progression.

In summary, this study hopes to reveal new candidate genes and key biological processes in the progression from NASH to cirrhosis and eventually to HCC using systems biology methods, providing a theoretical basis for further development of treatments for these diseases. The study particularly emphasizes the importance of the YWHAZ gene as a potential key prognostic biomarker in NASH, cirrhosis, and HCC, and explores the potential roles of other genes such as RAC1, HNRNPU, ITGAV, and UBE2N in NASH and HCC. Additionally, it discusses some HCC-specific genes like ITGB1, PRKCI, PPIA, and RAB7A, as well as NASH-specific genes like GSK3B, DAB2, PSME4, and PPP3CA. These findings help provide direction for future in vivo and in vitro studies to validate the roles of these candidate genes and their importance in disease progression.